Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$1.11 USD
-0.02 (-1.34%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $1.10 -0.01 (-0.45%) 7:26 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BOLT 1.11 -0.02(-1.34%)
Will BOLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BOLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BOLT
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
BOLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?
Other News for BOLT
Bolt Metals Completes $231K Private Placement
12 Health Care Stocks Moving In Wednesday's After-Market Session
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
Bolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)